Roche/Genentech
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 3 disclosed transactions, Roche/Genentech concentrates its licensing activity in Gastroenterology, Ophthalmology. Roche/Genentech pays a 1.50x premium over market median. Their most common deal structure is Acquisition, with an average disclosed value of $4.9B. Most recent activity: 2026.
Pipeline coverage & gaps
Roche/Genentech has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| AcquisitionPrimary | 2 | $7.0B | $7.0B |
| License | 1 | $50M | $670M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | RVT-3101 (RO7790121) | Telavant | ulcerative colitis | phase_3 | $7.0B | $7.0B |
| 2023 | RVT-3101 (RO7790121/afimkibart) | Roivant Sciences (Telavant) | ulcerative colitis / Crohn's disease | phase_3 | $7.1B | $7.1B |
| 2023 | OpRegen (RG6501) | Lineage Cell Therapeutics | Dry AMD, geographic atrophy | phase_2 | $50M | $670M |
How this is computed
For each Roche/Genentech deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 2.609, clamped to [0.7, 1.5].